Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 5 , ISSUE 2 ( July-December, 2015 ) > List of Articles

RESEARCH ARTICLE

Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey

Necla Tulek, Metin Ozsoy, Cigdem Moroglu, Meliha Cagla Sonmezer, Fatih Temocin, Gunay Tuncer Ertem, Fatma Sebnem Erdinc

Citation Information : Tulek N, Ozsoy M, Moroglu C, Cagla Sonmezer M, Temocin F, Tuncer Ertem G, Sebnem Erdinc F. Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey. Euroasian J Hepatogastroenterol 2015; 5 (2):95-97.

DOI: 10.5005/jp-journals-10018-1143

License: CC BY-NC 4.0

Published Online: 01-07-2015


Abstract

Background: Hepatitis A virus (HAV) can cause significant pathology in patients with chronic hepatitis B virus (HBV), however, HAV can be prevented by vaccination. The aim of this study was to determine the implication of vaccination against HAV vaccine in patients with chronic hepatitis B. Materials and methods: The seroprevalence of anti-HAV IgG antibodies was investigated in the patients with chronic hepatitis B. Anti-HAV IgG antibodies were detected by commercially available ELISA kit. Results: A total of 673 patients (354 males, 319 females with age range of 17–78 years) with chronic hepatitis B were included the study. Hepatitis A virus seropositivity rate was 34% in the patients younger than 20 years, 79% in the age group of 20 to 29 years, and 100% after 35 years of age. Discussion: Hepatitis A virus vaccination may be recommended for young adult patients with chronic hepatitis B in Turkey.


PDF Share
  1. Averhoff F, Khudyakov Y, Bell BP. Hepatitis A Virus. In: Bennetth JE, Dolin R, Blaser M, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Saunders, Elsevier; 2015. p. 2096-2110
  2. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis 2011 Dec 12;11:337
  3. The global prevalence of hepatitis A virus infection and susceptibility: a systematic review. Geneva: World Health Organization; 2010. WHO/IVB/10.0
  4. Changing epidemiology of hepatitis A infection in Izmir, Turkey. Vaccine 2011;29(37):6259-6261
  5. Hepatitis A seroprevalence in children and adolescents aged 1 to 18 years among a low socioeconomic population in Izmir, Turkey. Travel Med Infect Dis 2012;10(1):43-47. Graph 1: Anti-HAV IgG seroprevalence rate among the patients with chronic hepatitis B Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey Euroasian Journal of Hepato-Gastroenterology, July-December 2015;5(2):95-97 97 EJOHG 6. Uysal G, Tülek N, Güven MA.Çocukluk çağı viral hepatitlerde etyolojik ajanların dağılımı. Flora 1998;3:274-275
  6. Turkish national study team. Hepatitis A seroprevalence in a random sample of the Turkish population by simultaneous EPI cluster and comparison with surveys in Turkey. Turk J Pediatr 2002;44(3):204-210
  7. Hepatitis A seroprevalence and demographics in Turkish children in Ankara. Pediatr Int 2009;51(1):5-8
  8. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatol 2003;38(3):613-618
  9. Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology. Infection 2005;(3): 136-139
  10. Factors influencing the severity of acute viral hepatitis A. Korean J Hepatol 2010;16(3):295-300
  11. Hepatitis A immunisation in persons not previously exposed to hepatitis A. Cochrane Database Syst Rev 2012;7:CD009051
  12. Available at: http://www.cdc.gov/vaccines/ schedules/hcp/imz/child-adolescent.html1., accessed 05 April 2015
  13. Available at: http://www. cdc.gov/vaccines/schedules/hcp/adult.html, accessed 05 April 2015.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.